Here, we focus on the oncogenic role of TRIM65 in orchestrating metabolic and immune advantages in HCC using transgenic mouse models and identify TRIM65 as an essential promoter involved in the initiation and progression of HCC using two in situ models of HCC. This evidence concerns the gene TRIM65 and hepatocellular carcinoma.